DMAC

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

Retrieved on: 
Wednesday, April 17, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Stroke, Patient, ASTN, DMAC, DSM-IV codes, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke.
  • The company continues to work closely with its contract research organization (CRO), on re-engaging with study sites for the ReMEDy2 Trial.
  • The trial is intended to enroll approximately 350 patients at up to 100 sites globally.
  • The majority of the U.S. sites are expected to be activated by the end of the third quarter of 2024.

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Health, FDA, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Epilepsy, TPA, AIS, Patient, Tissue plasminogen activator, Stroke, G&A, Investment, Therapy, Pharmacovigilance, Nektar Therapeutics, Research, KLK1, Biostatistics, NKTR, Trial of the century, DSM-IV codes, NIHSS, Amgen, Data management, Pharmacy, Food, Cubist Pharmaceuticals, Neurology, Rankine scale, Shanghai Pharmaceuticals, DMAC, Acquisition, University, Yale University, Psychiatry, MRS, ASTN, Takeda, Patent, Bangladesh Technical Education Board, Probability, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.
  • Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2023 financial results.
  • Other income, net, was $1.9 million for the year ended December 31, 2023 compared to $0.4 million for 2022.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and full year quarter 2023 financial results on Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time:

DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

Retrieved on: 
Monday, January 29, 2024
Health, Neurology, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, DMAC, Patient, Poster, Conference, KLK1, AIS, American Heart

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS), today announced a poster presentation of the design and rationale for ReMEDy2, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the American Heart Association 2024 International Stroke Conference being held in Phoenix, AZ from February 7 – 9, 2024.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS), today announced a poster presentation of the design and rationale for ReMEDy2, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the American Heart Association 2024 International Stroke Conference being held in Phoenix, AZ from February 7 – 9, 2024.
  • The poster will be located in Poster Hall 5-6 (Poster Board CTP36).
  • Dr. Scott Kasner, ReMEDy2 trial National Principal Investigator, will be present to answer questions about the poster.
  • DiaMedica will also be exhibiting at the conference located in the main hall at booth 1021.

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Retrieved on: 
Monday, January 22, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Psychiatry, Cubist Pharmaceuticals, Amgen, Patient, Therapy, Employment, Neurology, Biostatistics, Data management, DMAC, Pharmacovigilance, Stroke, University, NKTR, Yale University, Acquisition, Epilepsy, Nektar Therapeutics, DSM-IV codes, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D.
  • as Chief Medical Officer.
  • “We are delighted to have Lorianne join our executive leadership team,” said Rick Pauls, DiaMedica’s President and Chief Executive Officer.
  • Dr. Masuoka received her medical degree from the University of California, Davis, where she also completed her residency in neurology.

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Health, FDA, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, TPA, Food, NIHSS, Investment, Clinical trial, DSM-IV codes, Patient, Research, AIS, DMAC, G&A, Stroke, Patent, Trial of the century, PPD, R, Hospital, ChromeOS, MRS, KLK1, Pharmaceutical industry, Cryptocurrency

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended September 30, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended September 30, 2023.
  • Management will host a conference call Tuesday, November 14, 2023, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and third quarter 2023 financial results.
  • These study modifications include focusing participant eligibility to those subjects with only moderate acute ischemic strokes in the anterior circulation.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and third quarter 2023 financial results on Tuesday, November 14, 2023, at 8:00 AM Eastern Time / 7:00 AM Central Time:

DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023

Retrieved on: 
Thursday, November 9, 2023
Health, Clinical Trials, General Health, Pharmaceutical, Cardiology, Biotechnology, KLK1, Conference, DMAC, Pharmaceutical industry, Financial adviser

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, today announced that Rick Pauls, its President and CEO and Dave Wambeke, its Chief Business Officer will be participating in the 14th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 16, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, today announced that Rick Pauls, its President and CEO and Dave Wambeke, its Chief Business Officer will be participating in the 14th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 16, 2023.
  • Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.

New Eye-Tracking Research Confirms Efficacy of Journalistic Transparency Indicators in Rebuilding Trust in News

Retrieved on: 
Thursday, September 14, 2023
Digital media, Skepticism, DMAC, Reuters, University, The Trust Project, Research, Disinformation, Organization, Trust, Best practice, Campuses of the University of Georgia, Misinformation, Ethics, Renewable energy, News

PACIFICA, Calif., Sept. 14, 2023 /PRNewswire/ -- Journalistic transparency elements earn user attention and significantly strengthen news credibility and trust, according to groundbreaking eye-tracking research announced today by the Trust Project, a nonpartisan, nonprofit global consortium of news organizations dedicated to addressing the crisis of trust and disinformation, and the University of Georgia's Digital Media Attention and Cognition Lab (DMAC).

Key Points: 
  • "This study equips news organizations with actionable insights to fortify their credibility and empower the public to distinguish fact from falsehood."
  • The in-person eye-tracking experiment, led by DMAC Lab Director Bart Wojdynski and Senior Research Associate Charlotte Varnum, was designed to better understand how people interact with the Trust Project's Trust Indicators® in online news articles.
  • In a landscape where much of the existing research serves only to highlight the loss of trust in news media, this study revealed tangible, research-backed solutions.
  • Design Matters: The way transparency elements and labels are designed - especially their prominence on the page - played a crucial role.

New Eye-Tracking Research Confirms Efficacy of Journalistic Transparency Indicators in Rebuilding Trust in News

Retrieved on: 
Thursday, September 14, 2023
Digital media, Skepticism, DMAC, Reuters, University, The Trust Project, Research, Disinformation, Organization, Trust, Best practice, Campuses of the University of Georgia, Misinformation, Ethics, News

PACIFICA, Calif., Sept. 14, 2023 /PRNewswire/ -- Journalistic transparency elements earn user attention and significantly strengthen news credibility and trust, according to groundbreaking eye-tracking research announced today by the Trust Project, a nonpartisan, nonprofit global consortium of news organizations dedicated to addressing the crisis of trust and disinformation, and the University of Georgia's Digital Media Attention and Cognition Lab (DMAC).

Key Points: 
  • "This study equips news organizations with actionable insights to fortify their credibility and empower the public to distinguish fact from falsehood."
  • The in-person eye-tracking experiment, led by DMAC Lab Director Bart Wojdynski and Senior Research Associate Charlotte Varnum, was designed to better understand how people interact with the Trust Project's Trust Indicators® in online news articles.
  • In a landscape where much of the existing research serves only to highlight the loss of trust in news media, this study revealed tangible, research-backed solutions.
  • Design Matters: The way transparency elements and labels are designed - especially their prominence on the page - played a crucial role.

DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

Retrieved on: 
Tuesday, September 12, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Vaccine, DMAC, Duquesne University, Drug delivery, Pharmacy, Stroke, CMC, DSM-IV codes, MedImmune, Human Genome Sciences, AstraZeneca, Bristol Myers Squibb, Bachelor of Pharmacy, Patient, University of Mumbai, Approved Drug Products with Therapeutic Equivalence Evaluations, Mercer University, Pharmaceutical industry, Science, GSK plc, Pfizer

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer.
  • Dr. Shah will lead the development of DiaMedica’s manufacturing operations for the late-stage drug candidate DM199.
  • “I am delighted to join DiaMedica at this pivotal time in the Company’s advancement,” said Dr. Shah.
  • He obtained his doctorate in Pharmaceutical Sciences from Mercer University, Atlanta, Georgia with a focus on Drug Delivery.

DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference

Retrieved on: 
Wednesday, September 6, 2023
Health, Neurology, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, DMAC, DSM-IV codes, Conference, Pharmaceutical industry, Security (finance)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 7th Annual Best Ideas Growth (BIG7) Conference in New York, on September 14, 2023.
  • Management will conduct one-on-one meetings with investors during the conference.
  • To receive additional information or to schedule a one-on-one meeting, please contact your Lake Street Capital Markets representative.